

January 27, 2026

To,

1. National Stock Exchange of India Limited
'G' Block, Exchange Plaza, Sandra Kurla Complex,
Sandra (East), Mumbai- 400 051.

2. BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
Mumbai- 400 001.

3. Board of Directors
Nureca Limited ("Company")
Andheri West B-205, Bldg -42, B wing, Dhanashree heights,
Azad Nagar Sangam CHS, Andheri West, Mumbai – 400053.

Sub: Disclosures under Regulation 29(1) and 29(2) of Securities and Exchange Board of India ("SEBI") (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("Takeover Regulations").

Dear Sir/Ma'am,

Please find attached the joint disclosure regarding the increase in the percentage of equity shareholding and Voting Rights of the promoter and promoter group in the Company, without any change in the number of equity shares held. This change is consequent to the buyback of equity shares of the Company, which was opened on December 18, 2025 and closed on December 24, 2025, and the subsequent extinguishment of shares on January 07, 2026. The disclosures are being made pursuant to Regulation 29(1) and 29(2) of the Takeovers Regulations.

Although such disclosures may not be required in terms of the SEBI Circular dated March 07, 2022, the same are being submitted as a matter of abundant caution and for greater clarity.

You are requested to take note of the same on your records.

Yours faithfully,

For and on behalf of

Acquirers being members of Promoter and Promoter Group

Saurabh Goyal Aryan Goyal Payal Goyal Smita Goyal

**Saurabh Goyal
(On behalf of Nectar Biopharma Private Limited)
Director
DIN: 00136037**

Joint Disclosures under Regulation 29(1) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A- Details of the Acquisition

Name of the Target Company (TC)	Nureca Limited ("TC" or "Company")		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	1. Saurabh Goyal 2. Aryan Goyal 3. Payal Goyal 4. Smita Goyal 5. Nectar Biopharma Private Limited		
Whether the acquirer belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	1. BSE Limited 2. National Stock Exchange of India Limited		
Details of the acquisition as follows	Number	% w.r.t. total share/voting Capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	64,97,176	64.97	64.97
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
c) Voting rights (VR) otherwise than by equity shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	-	-	-
e) Total (a+b+c+d)	64,97,176	64.97	64.97
Details of acquisition			
a) Shares carrying voting rights acquired	-	3.12	3.12
b) VRs acquired otherwise than by equity shares	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying category) acquired	-	-	-

d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
e) Total (a+b+c+d)	-	3.12	3.12
After the acquisition, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	64,97,176	68.09	68.09
b) VRs otherwise than by equity shares	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	-	-	-
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
e) Total (a+b+c+d)	64,97,176	68.09	68.09
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/encumbrance, etc.)	This change is consequent to the buyback of equity shares of the Company, which opened on December 18, 2025 and closed on December 24, 2025, and the subsequent extinguishment of shares on January 07, 2026. Thereby %age in equity share capital and Voting Rights in the Company have been increased, though there is no change in the number of shares held.		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	Not Applicable		
Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	January 07, 2026 (date of Extinguishment of shares due to Buyback)		
Equity share capital / total voting capital of the TC before the said acquisition	100001750		
Equity share capital/ total voting capital of the TC after the said acquisition	95419200		
Total diluted share/voting capital of the TC after the said acquisition	95419200		

Part-B*****Name of the Target Company: Nureca Limited**

Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Whether the acquirer belongs to Promoter/ Promoter group	PAN of the acquirer and/ or PACs
1. Saurabh Goyal	Yes	[REDACTED]
2. Aryan Goyal	Yes	[REDACTED]
3. Payal Goyal	Yes	[REDACTED]
4. Smita Goyal	Yes	[REDACTED]
5. Nectar Biopharma Private Limited	Yes	[REDACTED]

Signature of the acquirer / Authorised Signatory s

For and on behalf of

Acquirers being members of Promoter and Promoter Group**Saurabh Goyal****Aryan Goyal****Payal Goyal****Smita Goyal****Saurabh Goyal****(On behalf of Nectar Biopharma Private Limited)****Director****DIN: 00136037**

Place: Chandigarh

Date: January 27, 2026

Note:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(***) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated. The individual equity shareholding details of promoters and promoters' group in the Company before and after buyback is attached herewith as Annexure 1.

Annexure 1

Shareholding details of promoter and promoters' group of Nureca Limited

Name of Acquirer	Before the Buyback		Buy Back		After the Buyback		Difference
	No. of shares /voting rights	% w.r.t total share capital of TC	No. of shares / voting rights	% w.r.t total share capital of TC	No. of shares /voting rights	% w.r.t total share capital of TC	
Saurabh Goyal	32,17,214	32.17	0	-	32,17,214	33.72	1.55
Aryan Goyal	11,59,185	11.59	0	-	11,59,185	12.15	0.56
Payal Goyal	20,59,928	20.60	0	-	20,59,928	21.59	0.99
Smita Goyal	7	0.00	0	-	7	0.00	0.00
Nectar Biopharma Private Limited	60,842	0.61	0	-	60,842	0.64	0.03
Promoters Total	64,97,176	64.97	0	-	64,97,176	68.09	3.12
Public	35,02,999	35.03	-4,58,255	(04.58)	30,44,744	31.91	-3.12
Total	1,00,00,175	100.00	-4,58,255	(04.58)	95,41,920	100.00	-

Joint disclosures under Regulation 29(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Nureca Limited ("TC" or "Company")		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	1. Saurabh Goyal 2. Aryan Goyal 3. Payal Goyal 4. Smita Goyal 5. Nectar Biopharma Private Limited		
Whether the acquirer belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	1. BSE Limited 2. National Stock Exchange of India Limited		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	64,97,176	64.97	64.97
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
c) Voting rights (VR) otherwise than by equity shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	-	-	-
e) Total (a+b+c+d)	64,97,176	64.97	64.97
Details of acquisition			
a) Shares carrying voting rights acquired	-	3.12	3.12
b) VRs acquired otherwise than by equity shares	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying category) acquired	-	-	-
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
e) Total (a+b+c+d)	-	3.12	3.12
After the acquisition, holding of acquirer along with PACs of:			

a) Shares carrying voting rights	64,97,176	68.09	68.09
b) VRs otherwise than by equity shares	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	-	-	-
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
e) Total (a+b+c+d)	64,97,176	68.09	68.09
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/encumbrance, etc.)	This change is consequent to the buyback of equity shares of the Company, which opened on December 18, 2025 and closed on December 24, 2025, and the subsequent extinguishment of shares on January 07, 2026. Thereby %age in equity share capital and Voting Rights in the Company have been increased, though there have no change in the number of shares held.		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	Not Applicable		
Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC	January 07, 2026 (date of Extinguishment of shares due to Buyback)		
Equity share capital / total voting capital of the TC before the said acquisition	100001750		
Equity share capital/ total voting capital of the TC after the said acquisition	95419200		
Total diluted share/voting capital of the TC after the said acquisition	95419200		

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

The individual equity shareholding details of promoters and promoters' group in the Company before and after buyback is attached herewith as Annexure 1.

Signature of the acquirer / Authorised Signatory

For and on behalf of

Acquirers being members of Promoter and Promoter Group

Saurabh Goyal Aryan Goyal Payal Goyal Smita Goyal

Saurabh Goyal
(On behalf of Nectar Biopharma Private Limited)
Director
DIN: 00136037

Place: Chandigarh
Date: January 27, 2026

Annexure 1

Shareholding details of promoter and promoters' group of Nureca Limited

Name of Acquirer	Before the Buyback		Buy Back		After the Buyback		Difference
	No. of shares /voting rights	% w.r.t total share capital of TC	No. of shares / voting rights	% w.r.t total share capital of TC	No. of shares /voting rights	% w.r.t total share capital of TC	
Saurabh Goyal	32,17,214	32.17	0	-	32,17,214	33.72	1.55
Aryan Goyal	11,59,185	11.59	0	-	11,59,185	12.15	0.56
Payal Goyal	20,59,928	20.60	0	-	20,59,928	21.59	0.99
Smita Goyal	7	0.00	0	-	7	0.00	0.00
Nectar Biopharma Private Limited	60,842	0.61	0	-	60,842	0.64	0.03
Promoters Total	64,97,176	64.97	0	-	64,97,176	68.09	3.12
Public	35,02,999	35.03	-4,58,255	(04.58)	30,44,744	31.91	-3.12
Total	1,00,00,175	100.00	-4,58,255	(04.58)	95,41,920	100.00	-